Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Novacyt de volgende biotech raket!
Volgen
Voorproefje voor de dag dat de cijfers bekend raken........
snowhmr schreef op 27 januari 2021 15:44 :
Overheid in GB heeft contract met abingdon gecancelled enige wat ik kan vinden
Waar heb je dat gelezen?
www.ft.com/content/272a4903-4a0c-4736... Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at www.ft.com/tour. https://www.ft.com/content/272a4903-4a0c-4736-914a-ca5a4a51ba37 One of the companies tasked by the UK government with creating a rapid coronavirus antibody test had “all outstanding orders” cancelled this month, a development it did not disclose to the market when it issued a trading update on Tuesday. Abingdon Health leads the UK Rapid Test Consortium formed by a group of manufacturers in response to the government’s request to develop a homegrown test to reliably measure who has previously been infected by coronavirus. The Yorkshire-based biotechnology group listed on London’s Aim in mid-December, raising £22m and telling investors that the contract with the Department for Health and Social Care was critical to its business. The contract was for an initial 1m tests, with the possibility of millions more orders worth up to £75m. The company said on Tuesday it had delivered the initial batch on January 8. Three days later, DHSC cancelled “all outstanding orders” for Abingdon’s test, according to a letter seen by the Financial Times, citing the company’s failure to win approval from the medicines regulator for home use of the test by a Christmas deadline. “Abingdon Health did not obtain?.?.?.?approval for home use of its antibody lateral flow test (“LFT”) devices by 25 December 2020,” the government said in the letter to non-profit legal advocacy group the Good Law Project. “As a consequence, on 11 January 2021 the secretary of state exercised his contractual right under the August contract to cancel with immediate effect all outstanding orders placed with Abingdon Health.” The letter left open the possibility of the government buying Abingdon’s tests in future through its “dynamic purchasing system”, under which it buys from bidding companies on an ad hoc basis. The Good Law Project has been suing the government in judicial review proceedings to shed light on billions of pounds of contracts handed out by the UK government during the pandemic. It has challenged the way Abingdon’s was awarded, claiming the government did not sufficiently assess the accuracy of the tests and that there was not sufficient bidder competition. The government has denied the claims. The DHSC said that while it did not comment on ongoing legal proceedings, “we have always been clear that government contracts must deliver value for taxpayer money and we will take action in instances where this does not happen”. Abingdon said on Wednesday that as there had been no orders to cancel it had decided not to issue a statement to the market. “In consultation with advisers, the decision was made that there was not a statement to make as there were no outstanding orders with the DHSC and therefore no orders to be cancelled,” the company said in a statement to the Financial Times. It added: “Abingdon continues to manufacture the product for potential public and private sector use in the UK and internationally.” Abingdon’s December 11 prospectus said the government had not issued additional orders beyond the initial 1m but warned about the government’s termination rights in the event the company missed the Christmas approval deadline. “If the DHSC were to exercise such right, it could have a significant negative impact on the group’s results, overall financial condition and prospects,” the prospectus said. If no further orders were made, Abingdon’s board believed a similar volume could be sold to other buyers at the same or a higher price, according to the listing document. In Tuesday’s trading update Abingdon — whose shares are up 36 per cent since its float last month, valuing the business at £125m — said it expected revenues for the six months to the end of December to be in line with expectations at about £7.7m. “Regarding the current DHSC contract, as noted previously, this will expire on 14 February 2021 and, in line with the government’s shift to a dynamic purchasing strategy, the board expects that any future orders will be received via an application by the company to future DHSC tender notices,” the company said. Abingdon came under scrutiny last year after Public Health England researchers found its antibody test to be less accurate than the company’s 99 per cent claim. The group in November questioned the researchers’ methodology and said: “Our customer, DHSC, is satisfied with the performance of the test.” Daar gaat ODX door geraakt worden right?
Tommaco schreef op 27 januari 2021 15:55 :
[...]
Waar heb je dat gelezen?
Levert die NOV producten!
trab33 schreef op 27 januari 2021 15:47 :
[...].
proficiat ,zal wel binnen zijn
Dank, yup, aan 12,04
Zo, dat was even raar, om 6 euro op het scherm te zien, pffffffffffffff! Gelukkig heb ik stalen ballen! :-)
als vanouds ,stop losses er ff uit rammen en snel alles opkopen ,,,doet toch het beste vermoeden. was ff op wandel , toch gemiste kans om wat bij te kopen
Galapapositief schreef op 27 januari 2021 15:57 :
www.ft.com/content/272a4903-4a0c-4736... One of the companies tasked by the UK government with creating a rapid coronavirus antibody test had “all outstanding orders” cancelled this month, a development it did not disclose to the market when it issued a trading update on Tuesday.
Abingdon Health leads the UK Rapid Test Consortium formed by a group of manufacturers in response to the government’s request to develop a homegrown test to reliably measure who has previously been infected by coronavirus.
....
Dit is echt zwaar positief voor Novacyt lijkt me. Er ontstaat weer meer ruimte en vraag voor Nova om aan te voldoen. Opschieten met die ontwikkelingen dus.
Tommaco schreef op 27 januari 2021 15:55 :
[...]
Waar heb je dat gelezen?
Via het telegram app daar hebben ze ook de gehele verklaring dat de overheid na de order van 1 miljoen daarna nooit meer besteld heeft en niet gaat bestellen. ze gaan nu door met verkoop aan bedrijven en particulieren. Dit lijkt mij voor Nova juist positief. alleen wil mijn andere aandelen verkopen maar de giro werkt niet mee
Ze zijn weer eens gek aan het doen hoor. Nee, je krijgt mijn aandelen niet!
Er is een groep beleggers die erg goedkoop heeft kunnen inslaan! Novacyt 12,48 -0,50 -3,85 % 16:00:29 Novacyt 12,54 -0,44 -3,39 % 16:01:12
Eerder storm in glas water, dan het teken aan de wand.
voda schreef op 27 januari 2021 15:55 :
Hier worden vreemde spelletjes gespeeld zeg. Ik kan verder niets vinden.
Over de hele linie flikkerde alles zwaar naar beneden, geen idee, wat oorzaak was, maar je ziet nu alweer herstel ! Het was in iedergeval niet Trump! :-)
[Modbreak IEX: Gelieve op het Bpost forum over Bpost te discussiëren en niet hier, bericht is verwijderd.]
Herhaling van gisteren. Maar dan een uurtje vroeger.
oki cd schreef op 27 januari 2021 16:04 :
Voor de liefhebbers, bpost blijft goed liggen ;-)
Dank voor deze live update.
Even rondje lopen en de stand is anders.. ik heb gisteren alles verkocht, te veel om te grabbel te gooien, ben heel benieuwd wat er allemaal nog gaat komen.
oki cd schreef op 27 januari 2021 16:04 :
Voor de liefhebbers, bpost blijft goed liggen ;-)
Was een grap met een vette knipoog naar iemand....
Vollebeurs schreef op 27 januari 2021 16:06 :
[...]
Dank voor deze live update.
een geluk dat er hier zo informatief gepost wordt ,,
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee